parpex 10 tab
cadila hc. - pramipexole - tab - 1.5mg - 10
parpex 10 tab
cadila hc. - pramipexole - tab - 0.5mg - 10
parpex 10 tab
cadila hc. - pramipexole - tab - 1mg - 10
ranex 10 tab
cadila hc. - ranolazine - tab - 500mg - 10
recovorin 10 tab
cadila hc. - leucovorin calcium (calcium folinate) - tab - 15mg - 10
recovorin 2ml inj
cadila hc. - leucovorin calcium (calcium folinate) - inj - 7.5mg - 2ml
recovorin 5ml inj
cadila hc. - leucovorin calcium (calcium folinate) - inj - 50mg - 5ml
rhesuman inj. inj
cadila hc. - human anti-d immunoglobulin - inj - 300mcg - inj.
rhesumen pfs 2ml
cadila hc. - human anti-d immunoglobulin - 300mcg/2ml - 2ml
ofloxacin tablet, film coated
cadila pharmaceuticals limited - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin 200 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, usp and other antibacterial drugs, ofloxacin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ofloxacin tablets, usp are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. please see dosage and administration for specific recommendations. acute bacterial exacerbations of chronic bronchitis (abecb) due to haemophilus influenzae or streptococcus pneumonia . because fluoroquinolones, including ofloxacin, ha